Lumakras (Sotorasib) Market Global Overview and Strategic Regional Analysis 2021 to 2030
The Lumakras (Sotorasib) Market size was valued at USD XX million in 2020 and is predicted to reach USD XX million by 2030 with a CAGR of XX% from 2021-2030.Lumakras is a prescription drug mainly used to treat adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery. Also, these drugs are used to treat patients whose tumor has an abnormal KRAS G12C gene and have received at least one previous treatment for the cancer. This drug blocks the action of the abnormal protein that signals cancer cells to multiply, which in turn slows down the spread of cancer cells. Lumakras (Sotorasib) generally comes in a tablet form that is usually prescribed to be taken once daily before or after food.
It is the first treatment for non-small cell lung cancer (NSCLC) with a particular genetic mutation called KRAS G12C. It has been developed by Amgen and got approved by Food and Drug Administration (FDA) in May, 2021. The approval of Lumakras represents one of the major revolutions in the field of cancer treatment.
Access Full Description of this report at:-
https://www.nextmsc.com/report/lumakras-sotorasib-market
Competitive Landscape:
Currently, Sotarasib is solely manufactured by Amgen under the brand name of Lumakras. In June 2021, Amgen declared the combination study that results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer (CRC). These data show that combining LUMAKRAS (sotorasib) with Vectibix (panitumumab), will provide monoclonal antibody epidermal growth factor receptor (EGFR) inhibitor, demonstrated encouraging efficacy and safety. Also, recently in September 2021, Boehringer Ingelheim declared a clinical phase 1 collaboration with Amgen in order to evaluate the combination of BI 1701963, the most advanced SOS1: pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib).
Geographical Analysis:
North America holds the lion share of lumakras (sotorasib) market during the forecast period. This is attributed to factors such as the increasing prevalence of non-small cell lung cancer and the existence of large pharmaceutical companies actively participating in marketing activities, especially in the United States
However, Asia-Pacific is expected to show a steady rise in the lumakras (sotorasib) market. This is due to the increasing number of lung cancer cases in this region. Almost, 59% of the world’s lung cancer cases occurs in Asia and 21% of cancer deaths are due to lung cancer. Moreover, increasing demand for advanced treatment drugs and rising awareness among people about cancer and its treatment are the factors expected to propel the market growth in this region.
Request sample copy of this report at:-
https://www.nextmsc.com/3D-Printing-Market/request-sample
Market Dynamics and Trends:
Factors driving the lumakras (sotorasib) market growth are the ever-increasing cases of cancer and the high mortality due to it. This has created an unmet need for the development of new cancer treatment methods. Lumakras has also overcome the limitations of traditional cancer treatments. For instance, compared with conventional cancer treatments, Lumakras drugs have no side effects and also improve patient’s survival rates. According to the data presented by Amgen, in June 2021, Lumakras showed that the median overall survival (OS) of 124 evaluable patients was 12.5 months, and the majority of them had previously received platinum-based chemotherapy and immunotherapy. The results confirmed that the objective response rate (ORR) was 37.1%, the duration of response (DoR) was 11.1 months, the disease control rate (DCR) was 80.6%. and the patient achieved complete remission (total response rate reached 42 partial responses) as compared to previously reported results.
However, there are various side effects that occur due to the use of Sotorasib such as diarrhea, vomiting, nausea and others, which in turn limits the market growth to some extent. On the other hand, the government and pharmaceutical companies are increasing the development of preferential reimbursement policies that would help to reduce the cost of cancer treatment, thereby decreasing economic toxicity for patients. In addition, researchers are also evaluating the role of Lumakras in other solid tumors, as well as its combined use with other immunotherapy drugs, which is expected to create lucrative opportunities for the market players in the coming years.
Market Segmentations and Scope of the Study:
The lumakras (sotorasib) market is segmented by dose, by application and by geography. Based on type the market is divided into 960 mg, 480 mg and 240 mg. Based on application, the market is segmented into hospitals, drug centres, clinics, and others. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and RoW.
Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com
About Next Move Strategy Consulting:
Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.
For more insights, please visit, https://www.nextmsc.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lumakras (Sotorasib) Market Global Overview and Strategic Regional Analysis 2021 to 2030 here
News-ID: 2428377 • Views: …
More Releases from Next Move Strategy Consulting
Acne Medication Market Set for Exponential Growth with a Projected 3.2% CAGR by …
Introduction:
According to the Next Move Strategy Consulting, the Global Acne Medication Market size is anticipated to reflect a Compound Annual Growth Rate (CAGR) of 3.2% from 2024 to 2030.
The acne medication market is experiencing a transformative surge, driven by the increasing demand for effective solutions to address skincare concerns globally. As individuals prioritize skincare and beauty, the acne medication market emerges as a key player in providing innovative, targeted…
Unleashing the Potential of the Hemodialysis Market for Unprecedented Growth wit …
According to the Next Move Strategy Consulting, the Global Hemodialysis Market size is anticipated to reflect a Compound Annual Growth Rate (CAGR) of 3.60% from 2024 to 2030.
In recent years, the global healthcare landscape has witnessed a significant surge in demand for advanced renal care solutions, with the hemodialysis market emerging as a pivotal player in addressing the evolving needs of patients grappling with kidney-related issues.
Projections indicate that…
Managed Mobility Services Market Accelerates Towards USD 133.90 Billion Valuatio …
In a groundbreaking revelation, industry experts at Next Move Strategy Consulting unveil a compelling trajectory for the managed mobility services market, foreseeing an exceptional valuation of USD 133.90 billion by 2030. This robust ascent is underpinned by an extraordinary CAGR of 31.1%, signifying the pivotal role managed mobility services play in reshaping the digital landscape and empowering businesses with unparalleled mobility solutions.
Introduction:
Positioned as a linchpin in the broader landscape of…
The Infant Phototherapy Device Market Set for Remarkable Growth with a Projected …
Introduction:
According to the Next Move Strategy Consulting, the Global Infant Phototherapy Device Market size is anticipated to reflect a Compound Annual Growth Rate (CAGR) of 4.0% from 2024 to 2030.
The global infant phototherapy device market is poised for unprecedented growth, driven by the increasing demand for advanced neonatal care solutions and a growing focus on improving infant health outcomes. This comprehensive analysis delves into the key drivers, market segmentation,…
More Releases for Lumakras
Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight
DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
The pancreatic cancer market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the…
Lumakras Drug Market 2022 Global Insights and Business Scenario- Amgen Inc., Boe …
Lumakras Drug Market research added by the Absolute Markets Insights, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors.
Access the Free PDF sample of…
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights:
* NSCLC Targeting Lumakras Market Opportunity (US$ Million)
* Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
* Pharmacokinetics of Lumakras (Sotorasib)
* Dosage, Patent and Price Analysis
* Lumakras Ongoing Clinical Trials
* Global KRAS Protein Inhibitors Clinical Trials
Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase
The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management…
Global KRAS Inhibitors Market and Clinical Trials Forecast 2028
"Global KRAS Inhibitors Market and Clinical Trials Forecast 2028" Report Highlights:
* KRAS Inhibitors Market Opportunity: > USD 4.5 Billion by 2028
* Initially US To Dominate KRAS Inhibitors Market: >70% Market Share
* Number of KRAS Inhibitors In Trials: > 45 Drugs
* Number of Approved Drugs: 1 (Lumakras)
* Lumakras Dosage, Sales, Patent and Price Insight
* Solid Tumors Targeted Drugs Dominating The Clinical Trials
* Global KRAS Inhibitors Market Trends and Dynamics
* Global KRAS…
Construction Market is predicted to reach USD 14.41 trillion by 2030 with a CAGR …
The Construction Market size was valued at USD 7.28 trillion in 2021 and is predicted to reach USD 14.41 trillion by 2030 with a CAGR of 7.3% from 2022-2030.
Construction refers to maintenance, and repair of buildings or other immobile structures as well as building of roads and public service facilities. It also includes structural additions and alteration such as bearing walls, beams, and exterior walls. Moreover, each type of…
Lumakras (Sotorasib) Market Size, Status, Types, Applications, Key Players and F …
Lumakras is a prescription drug mainly used to treat adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery. Also, these drugs are used to treat patients whose tumor has an abnormal KRAS G12C gene and have received at least one previous treatment for the cancer. This drug blocks the action of the abnormal protein that signals…